Tazeen Ahmad
Stock Analyst at B of A Securities
(3.29)
# 1,023
Out of 5,182 analysts
224
Total ratings
47.59%
Success rate
2.37%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $262 → $292 | $226.66 | +28.83% | 13 | Apr 16, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $35 | $22.48 | +55.73% | 1 | Mar 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $29 | $22.30 | +30.04% | 17 | Mar 25, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $149 | $85.20 | +74.88% | 11 | Mar 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Buy | $97 → $93 | $69.22 | +34.35% | 20 | Feb 20, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $308.51 | +49.75% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $163.06 | +19.59% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $40.95 | -31.62% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $744.44 | +15.52% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $23.99 | +141.77% | 7 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $7 | $7.72 | -9.33% | 7 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $112 | $86.68 | +29.21% | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $30 | $28.71 | +4.49% | 5 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $46.29 | +14.50% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $95.72 | +8.66% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $783.74 | +13.18% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $20.98 | -23.74% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $102.06 | +31.30% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $6.46 | +23.84% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.90 | +68.54% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $10.79 | -62.93% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $33.59 | -76.18% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $19.94 | +35.41% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $10.29 | +172.11% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.45 | +323.28% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $128.04 | +39.80% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $19.16 | +14.82% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.60 | +87.50% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.49 | +3.52% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $6.10 | +63.93% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.31 | +358.02% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $9.52 | +57.56% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.76 | -46.81% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $4.52 | +32.74% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $29.95 | -49.92% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $330.99 | -81.87% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.76 | +809.09% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $136.41 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $20.39 | +1,371.31% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.67 | +237.08% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.55 | +87.87% | 6 | Oct 10, 2018 |
Ascendis Pharma
Apr 16, 2026
Maintains: Buy
Price Target: $262 → $292
Current: $226.66
Upside: +28.83%
Bicara Therapeutics
Mar 25, 2026
Initiates: Buy
Price Target: $35
Current: $22.48
Upside: +55.73%
ACADIA Pharmaceuticals
Mar 25, 2026
Upgrades: Buy
Price Target: $29
Current: $22.30
Upside: +30.04%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $139 → $149
Current: $85.20
Upside: +74.88%
PTC Therapeutics
Feb 20, 2026
Maintains: Buy
Price Target: $97 → $93
Current: $69.22
Upside: +34.35%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $308.51
Upside: +49.75%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $163.06
Upside: +19.59%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $40.95
Upside: -31.62%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $744.44
Upside: +15.52%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $23.99
Upside: +141.77%
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $7.72
Upside: -9.33%
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $86.68
Upside: +29.21%
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $28.71
Upside: +4.49%
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $46.29
Upside: +14.50%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $95.72
Upside: +8.66%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $783.74
Upside: +13.18%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $20.98
Upside: -23.74%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $102.06
Upside: +31.30%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $6.46
Upside: +23.84%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.90
Upside: +68.54%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $10.79
Upside: -62.93%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $33.59
Upside: -76.18%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $19.94
Upside: +35.41%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $10.29
Upside: +172.11%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.45
Upside: +323.28%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $128.04
Upside: +39.80%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $19.16
Upside: +14.82%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.60
Upside: +87.50%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.49
Upside: +3.52%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $6.10
Upside: +63.93%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.31
Upside: +358.02%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $9.52
Upside: +57.56%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.76
Upside: -46.81%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $4.52
Upside: +32.74%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $29.95
Upside: -49.92%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $330.99
Upside: -81.87%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.76
Upside: +809.09%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $136.41
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $20.39
Upside: +1,371.31%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.67
Upside: +237.08%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.55
Upside: +87.87%